Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 23, 2026.
Filed with NSE · ISIN INE044A01028 · · 7 pages · English
Summary by 6ix AI
Sun Pharmaceutical Industries Limited has issued a press release regarding its presentation at the ESMO Congress, detailing long-term follow-up data on UNLOXCYT for advanced cutaneous squamous cell carcinoma. The data highlights the efficacy and safety of UNLOXCYT, indicating a significant number of patients achieved a complete response. This filing serves to inform stakeholders about the upcoming presentation and the significance of the findings related to their treatment options.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sun Pharmaceutical Industries Limited on 6ix
Story so far
- Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 20, 2026.
- Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 01, 2026, titled "New LEQSELVI® (deuruxolitinib) Two-YearData in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026".
Earlier from Sun Pharmaceutical Industries
- Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 20, 2026.
- Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care
- New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026
- LIB Therapeutics and Sun Pharma Announce Global Licensing, Commercialization and Manufacturing Agreement for Lerodalcibep, a Novel PCSK9 Inhibitor, Ex-US and China; Lerodalcibep (Lyrokaul®) Approved in the EU
- Sun Pharmaceutical Industries Limited Press Release Sep 28 2026
Later from Sun Pharmaceutical Industries
All Sun Pharmaceutical Industries news releasesFollow Sun Pharmaceutical Industries into a list and get an email when it puts out news.
Follow Sun Pharmaceutical Industries